NUVATION BIO INC

Explore Nuvation Bio’s Q3 earnings call and pipeline updates, featuring next‑gen ROS1, IDH1, and DDC therapies, as the company targets drug‑resistance in oncology.

Explore Nuvation Bio (NUVB): 6.47% rally, $4.85 price, $1.6B cap, and 200‑day SMA at $5.52 – potential upside if pipeline breakthroughs hit.